YELLOW Sitting out on mixed signals.
Discipline is edge
Regime: YELLOW
The Picks
| Ticker | Scan Price | Gap % | RVOL | Catalyst | ML Hold Prob | ML Expected |
|---|---|---|---|---|---|---|
| CCC | $7.17 | 7.17 | 35.67 | M&A: Copart is among potential suitors bidding for CCC, a car insurance software firm, indicating acquisition interest. | — | — |
| XP | $16.20 | 3.18 | 25.30 | Earnings: XP rose after reporting Q2 2026 earnings that beat estimates and announcing a 2.3% class A share cancellation [via web] | — | — |
| EL | $95.18 | 12.85 | 17.44 | Earnings: Estée Lauder provided FY2027 guidance with revenue and adjusted EPS slightly above consensus, signaling management confidence in growth recovery. | — | — |
| MRK | $146.76 | 7.94 | 15.63 | Fda: Merck and Moderna announced positive Phase 3 trial results for intismeran autogene combined with KEYTRUDA showing statistically significant improvements in recurrence-free survival and distant metasta | — | — |
| JNJ | $272.90 | 4.01 | 15.38 | Fda: FDA cleared Johnson & Johnson’s AI-powered MONARCH QUEST 3 bronchoscopy update [via web] | — | — |
The Results
| Ticker | Entry | Entry Time | Exit | Exit Time | Method | P/L | % | Catalyst |
|---|---|---|---|---|---|---|---|---|
| CCC | $7.17 | $7.34 | 3:20 PM | Shadow | $243.95 | 2.44 | M&A: Copart is among potential suitors bidding for CCC, a car insurance software firm, indicating acquisition interest. | |
| XP | $16.20 | $16.30 | 3:20 PM | Shadow | $58.62 | 0.59 | Earnings: XP rose after reporting Q2 2026 earnings that beat estimates and announcing a 2.3% class A share cancellation [via web] | |
| EL | $95.18 | $99.47 | 3:20 PM | Shadow | $450.97 | 4.51 | Earnings: Estée Lauder provided FY2027 guidance with revenue and adjusted EPS slightly above consensus, signaling management confidence in growth recovery. | |
| MRK | $146.76 | $153.19 | 3:20 PM | Shadow | $437.24 | 4.38 | Fda: Merck and Moderna announced positive Phase 3 trial results for intismeran autogene combined with KEYTRUDA showing statistically significant improvements in recurrence-free survival and distant metasta | |
| JNJ | $272.90 | $274.66 | 3:20 PM | Shadow | $63.36 | 0.64 | Fda: FDA cleared Johnson & Johnson’s AI-powered MONARCH QUEST 3 bronchoscopy update [via web] |
Shadow Results
| Ticker | Shadow Entry | Shadow Exit | Exit Time | Method | Shadow P/L | % | Result | Catalyst |
|---|---|---|---|---|---|---|---|---|
| CCC | $7.17 | $7.34 | 3:20 PM | Shadow | $243.95 | 2.44 | WIN | M&A: Copart is among potential suitors bidding for CCC, a car insurance software firm, indicating acquisition interest. |
| XP | $16.20 | $16.30 | 3:20 PM | Shadow | $58.62 | 0.59 | WIN | Earnings: XP rose after reporting Q2 2026 earnings that beat estimates and announcing a 2.3% class A share cancellation [via web] |
| EL | $95.18 | $99.47 | 3:20 PM | Shadow | $450.97 | 4.51 | WIN | Earnings: Estée Lauder provided FY2027 guidance with revenue and adjusted EPS slightly above consensus, signaling management confidence in growth recovery. |
| MRK | $146.76 | $153.19 | 3:20 PM | Shadow | $437.24 | 4.38 | WIN | Fda: Merck and Moderna announced positive Phase 3 trial results for intismeran autogene combined with KEYTRUDA showing statistically significant improvements in recurrence-free survival and distant metasta |
| JNJ | $272.90 | $274.66 | 3:20 PM | Shadow | $63.36 | 0.64 | WIN | Fda: FDA cleared Johnson & Johnson’s AI-powered MONARCH QUEST 3 bronchoscopy update [via web] |
Things to Explore
Interested in our research, validation methodology, and trading system?
Get in TouchWork With Diana
Need a context architect to scaffold your AI agents and facilitate structured learning?
Visit goddev.aiThis post is part of a series documenting MorningEdge's development in real time. The knowledge base contains 0 books, papers, and lab reports totaling 0+ searchable chunks. The trading system described is paper trading only — no real capital is at risk.